- Home
- DNTH vs AKBA Comparison
DNTH vs AKBA Comparison
Compare DNTH & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- AKBA
- Stock Information
- Founded
- DNTH 2015
- AKBA 2007
- Country
- DNTH United States
- AKBA United States
- Employees
- DNTH N/A
- AKBA N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- DNTH Health Care
- AKBA Health Care
- Exchange
- DNTH Nasdaq
- AKBA Nasdaq
- Market Cap
- DNTH 780.2M
- AKBA 861.7M
- IPO Year
- DNTH N/A
- AKBA 2014
- Fundamental
- Price
- DNTH $26.50
- AKBA $2.96
- Analyst Decision
- DNTH Strong Buy
- AKBA Strong Buy
- Analyst Count
- DNTH 8
- AKBA 5
- Target Price
- DNTH $54.00
- AKBA $6.90
- AVG Volume (30 Days)
- DNTH 374.5K
- AKBA 4.0M
- Earning Date
- DNTH 11-06-2025
- AKBA 11-06-2025
- Dividend Yield
- DNTH N/A
- AKBA N/A
- EPS Growth
- DNTH N/A
- AKBA N/A
- EPS
- DNTH N/A
- AKBA N/A
- Revenue
- DNTH $4,854,000.00
- AKBA $203,733,000.00
- Revenue This Year
- DNTH N/A
- AKBA $38.23
- Revenue Next Year
- DNTH N/A
- AKBA $38.17
- P/E Ratio
- DNTH N/A
- AKBA N/A
- Revenue Growth
- DNTH 17.87
- AKBA 16.75
- 52 Week Low
- DNTH $13.37
- AKBA $1.24
- 52 Week High
- DNTH $32.27
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- DNTH 70.68
- AKBA 36.78
- Support Level
- DNTH $22.81
- AKBA $2.98
- Resistance Level
- DNTH $24.81
- AKBA $3.22
- Average True Range (ATR)
- DNTH 1.57
- AKBA 0.14
- MACD
- DNTH 0.22
- AKBA 0.00
- Stochastic Oscillator
- DNTH 91.57
- AKBA 14.29
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.